Abstract: Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives having the general formula wherein R, R1, R2, R3, R4 and R5, are as defined herein, or a non-toxic pharmaceutically acceptable salt, solvate or prodrug thereof. The atropisomers can modulate the large conductance calcium-activated K+ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels. In addition, the atropisomers can be stable, i.e., do not interconvert, for periods of up to one month, or more.
Type:
Grant
Filed:
December 17, 2003
Date of Patent:
September 6, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Vivekananda M. Vrudhula, Valentin Kala Gribkoff, Bireshwar Dasgupta, Christopher G. Boissard
Abstract: Novel aminoalkylthiazole derivatives of Formula I are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders responsive to the opening of the KCNQ potassium channels, including pain and migraine.
Abstract: The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.
Type:
Grant
Filed:
December 4, 2002
Date of Patent:
July 19, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Kuo-Long Yu, Xiangdong Wang, Yaxiong Sun, Christopher Cianci, Jan Willem Thuring, Keith Combrink, Nicholas Meanwell, Yi Zhang, Rita L. Civiello
Abstract: The invention encompasses a series of tetrahydroisoquinolines of formula I which are antagonists of the human melatonin MT2 receptor and are useful as chronobiotic and sleep agents.
Type:
Grant
Filed:
March 29, 2004
Date of Patent:
June 21, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Gene M. Dubowchik, Jonathan L. Ditta, Stephen R. Bertenshaw
Abstract: The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazole derivatives for the treatment of respiratory syncytial virus infection.
Type:
Grant
Filed:
November 7, 2002
Date of Patent:
June 21, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Kuo-Long Yu, Rita Lee Civiello, Mark R. Krystal, Kathleen F. Kadow, Nicholas A. Meanwell
Abstract: This invention describes a process for preparing hydroxyazapirones of Formula I from azapirones of Formula II. The process comprises treating azapirones with a strong base, monitoring enolate formation of the azapirone by IR spectroscopy, and reacting the enolate with a source of molecular oxygen in the presence of a reductant. The process is suitable for large scale production of hydroxyazapirones.
Type:
Grant
Filed:
August 7, 2003
Date of Patent:
May 24, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Jeffrey Depue, Atul S. Kotnis, Simon Leung, Eric D. Dowdy, Daniel J. Watson
Abstract: An analytical method and apparatus using principal component analysis of nuclear magnetic resonance (NMR) data for rapid molecular structure/function pattern recognition. The presence of a molecular substructure in an organic compound is determined by comparing principal components calculated from chemical shift values of the substructure in selected compounds with those calculated from the chemical shift values of the organic compound. Alternatively, principal components are calculated from the intensities of NMR signals for a full spectrum, or selected regions thereof, to determine whether an organic compound belongs to or is excluded from a set of structurally related compounds. Also, the presence of a pharmacophore in an organic compound can be determined by comparing the principal components derived from data on a set of compounds known to bind to a particular receptor, or have a common biological effect, with the principal components of the data set of the organic compound.
Type:
Grant
Filed:
April 11, 2002
Date of Patent:
May 17, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Feng Xu, Steven E. Klohr, David Detlefsen
Abstract: The present invention relates a series of compounds of Formula I wherein R1, R2, R3, and B are as defined in the specification. The compounds are useful for the inhibition of HIV integrase and for the treatment of AIDS or ARC by administering compounds of the formula.
Type:
Grant
Filed:
May 5, 2004
Date of Patent:
May 10, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Michael A. Walker, Hatice Belgin Gulgeze, Jacques Banville, Roger Remillard, Donald Corson
Abstract: This invention relates to a novel class of peptides having the Formula (I): which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.
Abstract: The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.
Type:
Grant
Filed:
August 19, 2003
Date of Patent:
January 18, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Kuo-Long Yu, Rita L. Civiello, Keith D. Combrink, Hatice Belgin Gulgeze, Ny Sin, Xiangdong Wang, Nicholas Meanwell, Brian Lee Venables, Yi Zhang, Bradley C. Pearc, Zhiwei Yin, Jan Willem Thuring
Abstract: The present invention relates to ketoamide and ketoester compounds of Formula (I):
wherein W is —NH— or —O—, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
Abstract: The novel crystalline bis hydrochloride monohydrate salt having the formula
and pharmaceutical dosage forms thereof is provided having use in the treatment of respiratory syncytial viral infection.
Type:
Grant
Filed:
December 5, 2002
Date of Patent:
May 18, 2004
Assignee:
Bristol-Myers Squibb Company
Inventors:
Christoph Gesenberg, David Paul Provencal, Srinivasan Venkatesh, Hua Wang
Abstract: The present invention relates generally to a novel class of imidazolidinones of Formula (I):
that are useful as serine protease inhibitors, and more particularly as Hepatitis C virus NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
Abstract: The present invention relates to compounds of Formula (I):
wherein A1 is methylene, ethylene or propylene group and A2 is N or CR5, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
Abstract: The present invention relates generally to a novel class of pyrimidinones of Formula (I):
that are useful as serine protease inhibitors, and more particularly as Hepatitis C virus NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
Type:
Grant
Filed:
December 12, 2001
Date of Patent:
November 25, 2003
Assignee:
Bristol-Myers Squibb Company
Inventors:
Peter William Glunz, Brent Dale Douty, Wei Han